- Home
- ANTX vs BRNS Comparison
ANTX vs BRNS Comparison
Compare ANTX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- BRNS
- Stock Information
- Founded
- ANTX 2017
- BRNS 2016
- Country
- ANTX United States
- BRNS United Kingdom
- Employees
- ANTX N/A
- BRNS N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- BRNS Health Care
- Exchange
- ANTX Nasdaq
- BRNS Nasdaq
- Market Cap
- ANTX 37.3M
- BRNS 38.7M
- IPO Year
- ANTX 2022
- BRNS 2021
- Fundamental
- Price
- ANTX $1.10
- BRNS $1.09
- Analyst Decision
- ANTX Buy
- BRNS Strong Buy
- Analyst Count
- ANTX 3
- BRNS 2
- Target Price
- ANTX $2.00
- BRNS $3.00
- AVG Volume (30 Days)
- ANTX 331.6K
- BRNS 49.3K
- Earning Date
- ANTX 05-13-2025
- BRNS 05-07-2025
- Dividend Yield
- ANTX N/A
- BRNS N/A
- EPS Growth
- ANTX N/A
- BRNS N/A
- EPS
- ANTX N/A
- BRNS N/A
- Revenue
- ANTX N/A
- BRNS $14,969,000.00
- Revenue This Year
- ANTX N/A
- BRNS N/A
- Revenue Next Year
- ANTX N/A
- BRNS N/A
- P/E Ratio
- ANTX N/A
- BRNS N/A
- Revenue Growth
- ANTX N/A
- BRNS 4381.74
- 52 Week Low
- ANTX $0.87
- BRNS $0.64
- 52 Week High
- ANTX $3.07
- BRNS $2.14
- Technical
- Relative Strength Index (RSI)
- ANTX 39.89
- BRNS 59.44
- Support Level
- ANTX $1.01
- BRNS $0.65
- Resistance Level
- ANTX $1.22
- BRNS $1.11
- Average True Range (ATR)
- ANTX 0.07
- BRNS 0.12
- MACD
- ANTX -0.01
- BRNS 0.02
- Stochastic Oscillator
- ANTX 38.17
- BRNS 91.23
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.